Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04553 |
| Species: | Homo sapiens |
| Position : | chr3:187559165-187589165 |
| Year: | 2015 |
| Title: | Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. |
| Genome Build: | hg19 |
| Enhancer Type: | Super-enhancer |
| Condition: | Disease |
| Disease Name: | B-Cell Lymphoma |
| PMID: | 26229090 |
| Tissue: | blood / hematopoietic system |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | Lymphoma Cell |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| High Throughput Method: | ChIP-seq |
| Low Throughput Method: | ChIP-qPCR/ChIP; 3C; RT-qPCR/qPCR |
| Target gene : | BCL6 |
| TF name : | MEF2B |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MEF2B | CDO in myogenesis | reactome | 29 |
| MEF2B | p38 MAPK pathway | panther | 31 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_04558 | chr3:187088165-187909165 | blood / hematopoietic system | malignant cell | B-Cell Lymphoma |